Bristol-Myers Squibb Company Announces Consolidated Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Earnings Guidance for the Year 2014
For the full year, the company reported total revenues of $16,385 million against $17,621 million a year ago. Earnings before income taxes were $2,891 million against $2,340 million a year ago. Net earnings were $2,580 million against $2,501 million a year ago. Net earnings attributable to company were $2,563 million against $1,960 million a year ago. Earnings per diluted common share were $1.54 against $1.16 a year ago. Non-GAAP net earnings attributable to company were $3,019 million against $3,364 million a year ago. Non-GAAP diluted earnings per common share were $1.82 against $1.99 a year ago.
The company announced that setting its 2014 GAAP EPS guidance range from $1.75 to $1.90 and confirming its non-GAAP EPS guidance range from $1.65 to $1.80. Both GAAP and non-GAAP guidance assume current exchange rates and the closing of the sale of the diabetes business to AstraZeneca in the first quarter of 2014. The financial guidance for 2014 excludes the impact of any potential future strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified. The non-GAAP 2014 guidance also excludes other specified items as discussed under 'use of Non-GAAP Financial Information.